Healthcare provider profile · identity verified

Amy R Rivera, APRN

Nurse Practitioner · KISSIMMEE, FL · NPI 1306236435

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	306	121
Amlodipine Besylate	Amlodipine Besylate	233	83
Levothyroxine Sodium	Levothyroxine Sodium	184	64
Losartan Potassium	Losartan Potassium	137	58
Pantoprazole Sodium	Pantoprazole Sodium	124	47
Ozempic	Semaglutide	116	32
Rosuvastatin Calcium	Rosuvastatin Calcium	114	48
Omeprazole	Omeprazole	113	47
Sertraline Hcl	Sertraline Hcl	107	38
Fluticasone Propionate	Fluticasone Propionate	105	65
Hydrochlorothiazide	Hydrochlorothiazide	104	41
Metformin Hcl	Metformin Hcl	103	38
Gabapentin	Gabapentin	101	44
Prednisone	Prednisone	85	74
Lisinopril	Lisinopril	80	37
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	77	73
Metoprolol Succinate	Metoprolol Succinate	71	29
Famotidine	Famotidine	66	27
Montelukast Sodium	Montelukast Sodium	61	28
Eliquis	Apixaban	59	26
Simvastatin	Simvastatin	59	26
Tamsulosin Hcl	Tamsulosin Hcl	58	27
Jardiance	Empagliflozin	57	20
Meloxicam	Meloxicam	57	23
Alprazolam	Alprazolam	54	21
Carvedilol	Carvedilol	47	19
Furosemide	Furosemide	47	21
Alendronate Sodium	Alendronate Sodium	42	16
Trazodone Hcl	Trazodone Hcl	42	20
Metoprolol Tartrate	Metoprolol Tartrate	38	15
Synthroid	Levothyroxine Sodium	38	12
Pravastatin Sodium	Pravastatin Sodium	37	16
Doxycycline Hyclate	Doxycycline Hyclate	36	36
Azithromycin	Azithromycin	35	34
Ciprofloxacin Hcl	Ciprofloxacin Hcl	35	32
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	35	29
Allopurinol	Allopurinol	34	12
Cephalexin	Cephalexin	29	26
Clopidogrel	Clopidogrel Bisulfate	29	11
Albuterol Sulfate Hfa	Albuterol Sulfate	28	13
Finasteride	Finasteride	27	11
Donepezil Hcl	Donepezil Hcl	26	11
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Spironolactone	Spironolactone	25	11
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Lorazepam	Lorazepam	24	suppressed
Baclofen	Baclofen	23	13
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	13
Tizanidine Hcl	Tizanidine Hcl	23	18
Valsartan	Valsartan	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Glimepiride	Glimepiride	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	15
Tramadol Hcl	Tramadol Hcl	16	11
Valacyclovir	Valacyclovir Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	11
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Methylprednisolone	Methylprednisolone	14	14
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Sucralfate	Sucralfate	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Methocarbamol	Methocarbamol	13	13
Tradjenta	Linagliptin	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	12
Atenolol	Atenolol	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error